Alerts will be sent to your verified email
Verify Email
BLISSGVS
|
Bliss GVS Pharma
|
Syncom Formulations
|
Jagsonpal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
6.83 % | 8.81 % | 12.82 % |
|
5yr Avg Net Profit Margin
|
8.7 % | 7.78 % | 8.95 % |
|
Price to Book
|
1.59 | 4.61 | 6.66 |
|
P/E
|
15.66 | 27.4 | 26.26 |
|
5yr Avg Cash Conversion Cycle
|
186.56 Days | 84.02 Days | -0.27 Days |
|
5yr Average Interest Coverage Ratio
|
14.68 | 39.83 | 56.07 |
|
5yr Avg ROCE
|
13.27 % | 12.74 % | 17.0 % |
|
5yr Avg Operating Profit Margin
|
17.03 % | 9.47 % | 10.5 % |
|
5 yr average Debt to Equity
|
0.11 | 0.2 | 0.02 |
|
5yr CAGR Net Profit
|
4.24 % | 19.56 % | 23.34 % |
|
5yr Average Return on Assets
|
5.31 % | 5.89 % | 9.97 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
35.44 % | 50.57 % | 67.65 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.93 % | 0.0 | -1.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bliss GVS Pharma
|
Syncom Formulations
|
Jagsonpal Pharma
|
|---|